MedTrace Logo

Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)

NCT02005757 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-06-26

No results posted yet for this study

Summary

The purpose of this study is to access the efficacy and safety of Mizoribine 150mg qid and 50mg tid in active rheumatoid arthritis patients unsuccessfully treated with disease-modifying antirheumatic drug.

Conditions

Interventions

DRUG

Bredinin tablet 150mg

Bredinin 150mg qd vs Bredinin 50mg tid

DRUG

Bredinin tablet 50mg

Bredinin 150mg qd vs Bredinin 50mg tid

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Sung Su Kim, M.D., Ph.D · Gangneng asan Medical center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-06-30
Completion
2016-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02005757 on ClinicalTrials.gov